CPHI South East Asia 2025
July 16-18, 2025
Kuala Lumpur, Malaysia
https://www.cphi.com/sea/en/home.html
News and Events
Subscribe to our press distribution list to receive the latest news about AMW.
Upcoming
Events
CPHI 2025
October 28-30, 2025
Frankfurt, Germany
https://www.cphi.com/europe/en/home.html
BIO-Europe 2025
November 3-5, 2025
Vienna, Austria
https://informaconnect.com/bioeurope/
Past
Events
Archive
Pharmapack
January 24-25, 2024 Paris, France https://www.pharmapackeurope.com/
read morePharmasynergy
February 08-09, 2024
London, UK
euroPLX84
February 26-27, 2024 Lisbon, Portugal
read moreBIO-Europe Spring
March 18-20, 2024
Barcelona, Spain
https://informaconnect.com/bioeurope-spring/
4th Wet AMD & Diabetic Eye Disease Drug Development
March 19-21, 2024
Boston, MA
https://wet-amd-drug-development.com/
BIO International Convention
June 03-06, 2024
San Diego, California
https://www.bio.org/events/bio-international-convention
CPHI South East Asia
July 10-12, 2024 Bangkok, Thailand https://www.cphi.com/sea/en/home.html
read moreCPHI 2024
October 08-10, 2024 Milan, Italy https://www.cphi.com/europe/en/home.html
read morePODD – Partnership Opportunities in Drug Delivery
October 28-29, 2024 Boston, USA https://poddconference.com
read moreBIO-Europe
November 04-06, 2024 Stockholm, Sweden https://informaconnect.com/bioeurope/
read morePharmaSynergyRx 2025
February 27-28, 2025
London, UK
https://pharma-synergy-conference.com/pharmasynergy-2025/
BIO-Europe Spring
March 17-19, 2025
Milan, Italy
https://informaconnect.com/bioeurope-spring/
DCAT Week 2025
March 17-20, 2025
New York City, USA
https://dcatweek.org/
AT Uro Congress
May 22-24, 2025
Vienna, Austria
EuroPLX
June 2-3, 2025
Lisbon, Portugal
Latest
News
AMW Receives first Notified Body Opinion by TÜV SÜD and Lays the Foundation for Further Approvals of Goserelin in the EU
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that it has achieved a key milestone in opening new markets within the European Union (EU) and beyond with the final report of the first Notified Body Opinion (NBO) for its goserelin implant.
read moreAMW reports financial results for fiscal 2022 and updates on corporate performance
AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, today released its financial results for the year ended December 31, 2022. AMW reported record consolidated sales for 2022 of €22.8 million and achieved operating profitability for the first time in the company’s history. The company also reported that Philipp Karbach will assume the position of chief executive officer (CEO) effective June 1, 2023, as Dr. Konstantin Petropoulos has decided to step down as CEO of AMW GmbH effective May 31, 2023, to pursue new opportunities. Philipp Karbach joined AMW in 2016, most recently in his role as Chief Operating Officer (COO) and Chief Financial Officer (CFO).
read moreAMW Appoints Professor Olivia Merkel to the Scientific Advisory Board
AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, today announced the appointment of Prof. Dr. Olivia Merkel, Professor of Drug Delivery at the Faculty of Chemistry and Pharmacy of Ludwig-Maximilians-Universität (LMU) Munich, as a member of its Scientific Advisory Board (SAB). Prof. Merkel is an internationally recognized expert in novel and targeted drug delivery systems, including RNA delivery systems. Her appointment will strengthen AMW’s scientific expertise in sustained-release delivery systems, such as biodegradable implants, and contribute to the company’s strategic development plans. With her appointment, Prof. Merkel succeeds Prof. Dr. Gerhard Winter, who will step down from his position on the Scientific Advisory Board.
read moreAMW and SAJA Pharmaceuticals sign license and supply agreement for commercialization of AMW’s goserelin implant
AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, and SAJA Pharmaceuticals, a leading regional drug manufacturer based in Jeddah, Saudi Arabia, with a presence in the MENA (North Africa and Middle East) states, announced today that they have entered into an exclusive licensing and supply agreement. The agreement covers the commercialization of AMW’s goserelin implant in the Kingdom of Saudi Arabia.
read moreFurther EU Marketing Authorizations for AMW’s Leuprorelin Implant for the Treatment of Hormone-Sensitive Tumors
AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, announced today that the leuprorelin implant it developed has received additional marketing approvals in two European Union countries. Leuprorelin enables symptomatic therapy of hormone-sensitive tumors, such as prostate cancer, and of certain gynecological diseases. AMW’s leuprorelin implant is now approved as a cost-effective therapy in over ten countries worldwide.
read more